Evidence map›Paper›PMID 42327250›Full record

ArticlebioRxiv : the preprint server for biology2026

Egyptian rousette bat humoral immunity to H9 influenza hemagglutinin.

Anne A Roffler, Bruno Bonnettaz, Emerson Glassey, Connor L Murphy, Sophia L Sordilla, Ceili L Peng, Daniel P Maurer, Eda Altan, Kristian M Forbes, Tarja Sironen and 2 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anne A RofflerRagon Institute of Mass General, MIT, and Harvard; Cambridge, MA, USA.
Bruno BonnettazDepartment of Microbiology, Icahn School of Medicine at Mount Sinai; New York, NY, USA.
Emerson GlasseyRagon Institute of Mass General, MIT, and Harvard; Cambridge, MA, USA.
Connor L MurphyRagon Institute of Mass General, MIT, and Harvard; Cambridge, MA, USA.
Sophia L SordillaRagon Institute of Mass General, MIT, and Harvard; Cambridge, MA, USA.
Ceili L PengRagon Institute of Mass General, MIT, and Harvard; Cambridge, MA, USA.
Daniel P MaurerRagon Institute of Mass General, MIT, and Harvard; Cambridge, MA, USA.
Eda AltanDepartment of Virology, University of Helsinki; Helsinki, Finland.
Kristian M ForbesDepartment of Biological Sciences, University of Arkansas; Fayetteville, AR, USA.
Tarja SironenDepartment of Virology, University of Helsinki; Helsinki, Finland.
Goran BajicMicrobiology Program, Massachusetts Institute of Technology, Cambridge MA, USA.
Aaron G SchmidtRagon Institute of Mass General, MIT, and Harvard; Cambridge, MA, USA.ORCID 0000-0003-3627-2553

Funding

Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component A: Vaccine Center75N93019C00050 · NIAID · DUKE UNIVERSITY · PI MOODY, TONY · 2019 to 2025
$69.1M
NCCAT: National Center for CryoEM Access and Training- Supplement for Windows 10 and FFIU24GM129539 · NIGMS · NEW YORK STRUCTURAL BIOLOGY CENTER · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2018 to 2023
$53.9M
Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
Virology CoreP01AI089618 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI STEPHEN COPLAN HARRISON · 2011 to 2026
$40.0M
COVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0M
Glacios 2 Cryo-TEM for Structure AnalysisS10OD036213 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI AGGARWAL, ANEEL K. · 2024 to 2024
$2.0M
Big Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0M
NCATS NIH HHS UL1 TR004419NIAID NIH HHS P01 AI089618NIGMS NIH HHS U24 GM129539NIH HHS 75N93019C00050NIH HHS S10 OD026880NIH HHS S10 OD030463NIH HHS S10 OD036213
6 · The paper itself

Abstract

In mammals, antibodies are central to antiviral defense, but they can also impose selective pressure that drives viral evolution. The interplay between viral antigenic variation and host antibody diversification constitutes a molecular arms race that influences pathogenicity, transmission, and spillover risk. Bats are reservoirs for zoonotic viruses with pandemic potential yet they appear to tolerate infection without overt disease. Although distinctive features of bat innate immunity have been described, the role of adaptive immunity-particularly antibody-mediated responses-remains largely undefined. Moreover, how antibody evolutionary pressure operates in bats is unknown, in part because tools to interrogate bat B cell responses at the monoclonal level are limited. Here, we developed a yeast surface display library of bat antibodies derived from splenic RNA of wild-caught Egyptian rousette bats to interrogate humoral responses to the bat-derived H9 influenza hemagglutinin. We isolated monoclonal antibodies recognizing the hemagglutinin (HA) antigen and defined their gene usage, somatic hypermutation frequency, binding affinities, and breadth. We then used cryo-EM to structurally characterize three bat antibodies in complex with HA engaging distinct antigenic sites. Together, these data enable direct comparison with human anti-influenza antibodies highlighting similarities in humoral immunity across mammals and provides a tool to examine bat antibody responses to other potential zoonotic viruses.

Identifiers

PMID42327250
PMCPMC13278081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.